LLY

1,034.66

-2.08%↓

JNJ

205.59

+1.04%↑

ABBV

229.43

+2.73%↑

UNH

336.82

+3.99%↑

AZN

90.8

+0.33%↑

LLY

1,034.66

-2.08%↓

JNJ

205.59

+1.04%↑

ABBV

229.43

+2.73%↑

UNH

336.82

+3.99%↑

AZN

90.8

+0.33%↑

LLY

1,034.66

-2.08%↓

JNJ

205.59

+1.04%↑

ABBV

229.43

+2.73%↑

UNH

336.82

+3.99%↑

AZN

90.8

+0.33%↑

LLY

1,034.66

-2.08%↓

JNJ

205.59

+1.04%↑

ABBV

229.43

+2.73%↑

UNH

336.82

+3.99%↑

AZN

90.8

+0.33%↑

LLY

1,034.66

-2.08%↓

JNJ

205.59

+1.04%↑

ABBV

229.43

+2.73%↑

UNH

336.82

+3.99%↑

AZN

90.8

+0.33%↑

Search

Quanterix Corp

Deschisă

SectorSănătate

7.29 5.5

Rezumat

Modificarea prețului

24h

Curent

Minim

6.74

Maxim

7.42

Indicatori cheie

By Trading Economics

Venit

-3.5M

-34M

Vânzări

16M

40M

Marjă de profit

-83.479

Angajați

471

EBITDA

5.7M

-31M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-13.92% downside

Statistici piață

By TradingEconomics

Capitalizare de piață

88M

326M

Deschiderea anterioară

1.79

Închiderea anterioară

7.29

Sentimentul știrilor

By Acuity

50%

50%

162 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Quanterix Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 dec. 2025, 17:29 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Laurentian Bank Shares Hit Two-Year High on Plans for Break-Up, Takeover

2 dec. 2025, 16:21 UTC

Câștiguri

Scotiabank Aiming for Earnings Growth After Capital Markets Buoy Results in Latest Quarter -- Update

2 dec. 2025, 16:18 UTC

Câștiguri

Correction to Scotiabank Quarterly Earnings Buoyed Article

2 dec. 2025, 23:53 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

2 dec. 2025, 22:48 UTC

Câștiguri

Marvell's Stock Soars On Data Center Forecast -- Barrons.com

2 dec. 2025, 22:12 UTC

Market Talk

Australian 3Q GDP To Show Modest Recovery In Play -- Market Talk

2 dec. 2025, 22:03 UTC

Market Talk

Minerals 260's Resource Upgrade Looks Impressive -- Market Talk

2 dec. 2025, 22:00 UTC

Market Talk

Global Equities Roundup: Market Talk

2 dec. 2025, 22:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 dec. 2025, 22:00 UTC

Market Talk

Fletcher Building Loses Bull Due to Tame Housing-Market Recovery -- Market Talk

2 dec. 2025, 21:56 UTC

Câștiguri

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dec. 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

2 dec. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 dec. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2 dec. 2025, 21:44 UTC

Câștiguri

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dec. 2025, 21:38 UTC

Market Talk

Sky Network TV Has Path to Grow Dividend by 33% -- Market Talk

2 dec. 2025, 21:19 UTC

Câștiguri

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dec. 2025, 20:06 UTC

Market Talk

Oil Futures Fall Amid Russia-Ukraine Peace Talks -- Market Talk

2 dec. 2025, 19:55 UTC

Market Talk

Natural Gas Futures Fall Amid Uncertain Weather Forecasts -- Market Talk

2 dec. 2025, 19:53 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

2 dec. 2025, 19:53 UTC

Market Talk
Câștiguri

Scotiabank ROE Target Viewed as Possibly Conservative -- Market Talk

2 dec. 2025, 19:24 UTC

Market Talk

Analysts Project Uptick in U.S. Ethanol Stocks -- Market Talk

2 dec. 2025, 19:06 UTC

Market Talk

Precious Metals Step Back After Silver Sets Record -- Market Talk

2 dec. 2025, 18:27 UTC

Achiziții, Fuziuni, Preluări

Kraken to Acquire Backed Finance AG

2 dec. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 dec. 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2 dec. 2025, 15:17 UTC

Market Talk

Natural Gas Extends Gains Amid Cold Weather -- Market Talk

2 dec. 2025, 14:47 UTC

Market Talk

BOE Likely to Cut Rates Further, Weakening Sterling -- Market Talk

2 dec. 2025, 14:38 UTC

Market Talk

Silver Steps Back From Record Levels -- Market Talk

2 dec. 2025, 14:31 UTC

Market Talk
Câștiguri

Scotiabank Strong Quarter Driven By Capital Markets Growth -- Market Talk

Comparație

Modificare preț

Quanterix Corp Așteptări

Obiectiv de preț

By TipRanks

-13.92% jos

Prognoză pe 12 luni

Medie 6 USD  -13.92%

Maxim 7 USD

Minim 5 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuanterix Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

3 ratings

0

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.34 / 6.015Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

162 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
help-icon Live chat